Off-Label Semaglutide for Weight Loss: Real-World User Behavior and Outcomes
Real-world analysis of off-label semaglutide use for weight loss reveals user behavior patterns, effectiveness outside clinical trials, and adherence challenges.
Quick Facts
What This Study Found
Real-world analysis of off-label semaglutide use for weight loss reveals user behavior patterns, effectiveness outside clinical trials, and adherence challenges.
Key Numbers
74.6% of Kuwaiti adults are classified as overweight or obese. The survey captured usage patterns, weight changes, and satisfaction across Arab populations.
How They Did This
Clinical or preclinical study with methodology detailed in the full publication.
Why This Research Matters
This finding has implications for the millions of patients using or considering peptide-based therapies.
The Bigger Picture
This study adds to the rapidly expanding evidence base for peptide-based therapeutics across multiple medical specialties.
What This Study Doesn't Tell Us
Study-specific limitations are discussed in the full publication. As with all research, findings should be interpreted in the context of study design and population.
Questions This Raises
- ?What are the long-term implications of these findings?
- ?How do these results compare to other studies in this area?
- ?What further research is needed to confirm and extend these findings?
Trust & Context
- Key Stat:
- Key finding Real-world analysis of off-label semaglutide use for weight loss reveals user behavior patterns, eff
- Evidence Grade:
- Evidence grade assessment based on study design and methodology detailed in the full publication.
- Study Age:
- Published in 2025. Reflects current state of peptide therapeutic research.
- Original Title:
- Real-World Off-Label Use of Semaglutide for Weight Reduction: User Behavior, Effectiveness, and Satisfaction.
- Published In:
- Patient preference and adherence, 19, 3373-3385 (2025)
- Authors:
- Al-Qaaneh, Ayman M, Qunaibi, Eyad A, Al-Fraihat, Natalia A, Abu-Aisheh, Baraa E, Rabea, Sameh, Al Aloul, Adnan A, Matahen, Rajaa, Annabi, Firas O
- Database ID:
- RPEP-09830
Evidence Hierarchy
Frequently Asked Questions
What does this study mean for patients?
Real-world analysis of off-label semaglutide use for weight loss reveals user behavior patterns, effectiveness outside clinical trials, and adherence challenges.
How reliable are these findings?
The evidence level depends on study design. Clinical trials provide stronger evidence than case reports. Consult the full publication and discuss with your healthcare provider.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09830APA
Al-Qaaneh, Ayman M; Qunaibi, Eyad A; Al-Fraihat, Natalia A; Abu-Aisheh, Baraa E; Rabea, Sameh; Al Aloul, Adnan A; Matahen, Rajaa; Annabi, Firas O. (2025). Real-World Off-Label Use of Semaglutide for Weight Reduction: User Behavior, Effectiveness, and Satisfaction.. Patient preference and adherence, 19, 3373-3385. https://doi.org/10.2147/PPA.S549716
MLA
Al-Qaaneh, Ayman M, et al. "Real-World Off-Label Use of Semaglutide for Weight Reduction: User Behavior, Effectiveness, and Satisfaction.." Patient preference and adherence, 2025. https://doi.org/10.2147/PPA.S549716
RethinkPeptides
RethinkPeptides Research Database. "Real-World Off-Label Use of Semaglutide for Weight Reduction..." RPEP-09830. Retrieved from https://rethinkpeptides.com/research/al-qaaneh-2025-realworld-offlabel-use-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.